Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

NCT03721068 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Osteosarcoma

Interventions

BIOLOGICAL: iC9.GD2.CAR.IL-15 T-cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]